-
Samyang Holdings Partners with Yxintent for Lafullen Dermal Filler in China
•
South Korea-based Samyang Holdings Biopharm Group has secured a partnership with Hangzhou-based Yxintent, a specialist in medical devices and aesthetics, for its dermal filler product Lafullen. The partnership deal grants Yxintent the development and commercialization rights to Lafullen in China, marking a significant step for Samyang as it expands into…
-
Sequoia Capital to Split into Three Units, Including Independent China and India/SEA Divisions
•
US-based investment fund Sequoia Capital has declared plans to reorganize its business into three distinct units, effective from March 2024. This strategic move includes the establishment of a separate China unit to be renamed Hongshan, an India/South-east Asia unit, and the US/Europe division which will retain the Sequoia Capital name.…
-
Jacobio Pharma Gets Green Light for Phase I/IIa Study of PARP7 Inhibitor JAB-26766
•
China-based Jacobio Pharma (HKG: 1167) has announced receiving approval in China to initiate a Phase I/IIa clinical study for its in-house developed PARP7 inhibitor, JAB-26766, targeting advanced solid tumors. JAB-26766: A Potential Treatment for Squamous CancersThe oral small molecule PARP7 inhibitor is under development for the treatment of squamous non-small…
-
BioMarin Pharmaceutical to Discontinue Vimizim Import License in China
•
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has announced its decision not to renew the Import Drug License (IDL) for Vimizim (elosulfase alfa) in China when it expires in May 2024. The company is currently exploring feasible ways to ensure a continuous supply to patients currently undergoing treatment. Challenges in China’s Market…
-
Vcanbio Receives NMPA Approval for VUM02 Stem Cell Therapy in Liver Failure and ARDS
•
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced receiving clinical trial approvals from the National Medical Products Administration (NMPA) for its VUM02, a human umbilical cord-derived mesenchymal stem cell therapy. The Category 1 therapeutic biologic product is set to be assessed in acute-on-chronic liver failure (ACLF)…
-
Dizal Pharmaceutical Presents Updates on Sunvozertinib and Golidocitinib at ASCO 2023
•
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented updates on the clinical development of its next-generation epidermal growth factor receptor (EGFR) inhibitor sunvozertinib (DZD9008) and JAK1 inhibitor golidocitinib (DZD4205) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Sunvozertinib: A Promising EGFR Inhibitor for NSCLCSunvozertinib, under development for…
-
Abbisko Therapeutics’ Pimicotinib Earns PRIME Status for TGCT from EMA
•
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that its Category 1 drug ABSK021 (pimicotinib) has received Priority Medicine (PRIME) status from the European Medicines Agency (EMA) for the treatment of inoperable tenosynovial giant cell tumor (TGCT). This decision comes on the heels of positive results from an…
-
NMPA Approves Shenzhen Core Medical’s Implantable Left Ventricular Assist System
•
The National Medical Products Administration (NMPA) has issued market approval for the implantable left ventricular assist system developed by China-based Shenzhen Core Medical Technology Co., Ltd. This marks the fourth such device to reach the market in China, expanding options for patients with advanced heart failure. Product Composition and Clinical…
